Renaissance Technologies LLC lowered its stake in LivaNova PLC (NASDAQ:LIVN – Free Report) by 12.0% during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 152,394 shares of the company’s stock after selling 20,700 shares during the quarter. Renaissance Technologies LLC owned approximately 0.28% of LivaNova worth $8,354,000 as of its most recent SEC filing.
Several other institutional investors and hedge funds have also bought and sold shares of the stock. New York State Teachers Retirement System boosted its holdings in shares of LivaNova by 0.3% in the 1st quarter. New York State Teachers Retirement System now owns 64,322 shares of the company’s stock valued at $3,598,000 after buying an additional 200 shares during the last quarter. Arizona State Retirement System lifted its stake in LivaNova by 2.0% in the second quarter. Arizona State Retirement System now owns 15,104 shares of the company’s stock valued at $828,000 after acquiring an additional 299 shares during the last quarter. State of Michigan Retirement System grew its position in shares of LivaNova by 2.3% in the 1st quarter. State of Michigan Retirement System now owns 13,211 shares of the company’s stock valued at $739,000 after acquiring an additional 300 shares during the period. Fifth Third Bancorp increased its stake in shares of LivaNova by 97.1% during the 2nd quarter. Fifth Third Bancorp now owns 674 shares of the company’s stock worth $37,000 after purchasing an additional 332 shares during the last quarter. Finally, Hexagon Capital Partners LLC raised its holdings in shares of LivaNova by 117.8% in the 2nd quarter. Hexagon Capital Partners LLC now owns 684 shares of the company’s stock valued at $37,000 after purchasing an additional 370 shares during the period. Institutional investors own 97.64% of the company’s stock.
LivaNova Price Performance
LivaNova stock opened at $51.48 on Wednesday. The company has a market capitalization of $2.79 billion, a price-to-earnings ratio of -85.80 and a beta of 1.00. The stock’s 50 day moving average is $48.78 and its 200-day moving average is $53.34. The company has a current ratio of 3.45, a quick ratio of 2.94 and a debt-to-equity ratio of 0.49. LivaNova PLC has a 12 month low of $42.75 and a 12 month high of $64.47.
Wall Street Analysts Forecast Growth
A number of equities analysts recently commented on LIVN shares. Needham & Company LLC lifted their price target on LivaNova from $72.00 to $75.00 and gave the stock a “buy” rating in a report on Wednesday, July 31st. Robert W. Baird raised LivaNova from a “neutral” rating to an “outperform” rating and boosted their target price for the stock from $55.00 to $66.00 in a report on Tuesday, September 17th. Stifel Nicolaus increased their price target on LivaNova from $70.00 to $72.00 and gave the company a “buy” rating in a research note on Thursday, July 25th. Finally, Baird R W raised shares of LivaNova from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, September 17th. One analyst has rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus price target of $70.80.
Check Out Our Latest Report on LIVN
LivaNova Company Profile
LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.
Further Reading
- Five stocks we like better than LivaNova
- What Are the U.K. Market Holidays? How to Invest and Trade
- Biohaven Stock Soars on Drug Trial Results: Time to Jump In?
- Consumer Staples Stocks, Explained
- Is AMD a Legitimate Threat to NVIDIA? What Investors Should Watch
- How to Invest in the FAANG Stocks
- Novo Nordisk’s Setback Won’t Last: A Game-Changing Drug Emerges
Want to see what other hedge funds are holding LIVN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for LivaNova PLC (NASDAQ:LIVN – Free Report).
Receive News & Ratings for LivaNova Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LivaNova and related companies with MarketBeat.com's FREE daily email newsletter.